The company has two clinical utility studies underway and one large clinical validity study slated for publication later this year.
An analysis has found that the odds of getting a diagnosis through WES or WGS is 8.3 times greater than it is through chromosomal microarrays.
The projects, organized by Friends of Cancer Research in the US and the Quality Assurance Initiative Pathology (QuIP) in Germany, are comparing different TMB assays.
While a randomized-controlled trial is underway, Genomind hopes data from a new case-control study will convince insurers its PGx test can reduce healthcare utilization costs.
Under a collaboration with GeneDx, Boston Children's has rapidly sequenced the exomes of 20 NICU babies and have arrived at a likely diagnosis in around 85 percent.
Using a blood volume of 100 μL, the test demonstrated a sensitivity of 90.2 percent for the diagnosis of blood-culture positive sepsis episodes.
The study, launched today, aims to evaluate the use of liquid biopsy and natural killer cell testing for the early detection of recurrent breast cancer.
Results of a new study show that patients guided to targeted therapy based on ctDNA get the same benefits as those who got tissue-based tests in initial clinical trials.
Caris Life Sciences also found that time-to-next treatment could be a surrogate endpoint for survival.
A genetic testing utilization service launched by Stanford in 2015 helped cut the number of inappropriately ordered tests in half and saved about $250,000 during the first year.
The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.
Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.
In Science this week: in vitro generation of human reproductive cells, and more.
Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.